Scilex Holding (SCLX) Net Margin (2022 - 2026)
Scilex Holding (SCLX) posted quarterly Net Margin of 503.14% for Q1 2026, up 1846.0% year-over-year from 25.86% in Q1 2025, and up 26.46% on a QoQ basis from 684.13% in Q4 2025.
Scilex Holding (SCLX) Net Margin (2022 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Net Margin for 5 consecutive years, with 503.14% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin rose 1846.0% year-over-year to 503.14%; the TTM figure through Mar 2026 stood at 1238.13% (down 107364.0% YoY), while the FY2025 annual figure was 1328.34%, down 118396.0% from the prior year.
- Net Margin came in at 503.14% for Q1 2026 at Scilex Holding, up from 684.13% in the prior quarter.
- The five-year high for Net Margin was 188.99% in Q3 2022, with the low at 2435.93% in Q3 2025.
- Average Net Margin over 5 years is 438.51%, with a median of 225.06% recorded in 2022.
- Across the five-year window, Net Margin surged 84115 bps in 2024 and plunged 240553 bps in 2025, its largest moves.
- Year by year, Net Margin stood at 150.05% in 2022, then decreased by 6 bps to 158.97% in 2023, then surged by 35 bps to 103.05% in 2024, then tumbled by 564 bps to 684.13% in 2025, then grew by 26 bps to 503.14% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 503.14%, 684.13%, and 2435.93% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 37.36% |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 21.76% |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 4.65% |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 329.02% |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -25.84% |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 21.11% |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 29.04% |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -0.56% |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | -503.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -503.14% |
| Dec 31, 2025 | -684.13% |
| Sep 30, 2025 | -2,435.93% |
| Jun 30, 2025 | -869.65% |
| Mar 31, 2025 | -521.60% |
| Dec 31, 2024 | -103.05% |
| Sep 30, 2024 | -30.40% |
| Jun 30, 2024 | -229.58% |
| Mar 31, 2024 | -223.97% |
| Dec 31, 2023 | -158.97% |
| Sep 30, 2023 | -871.54% |
| Jun 30, 2023 | -211.80% |
| Mar 31, 2023 | -290.62% |
| Dec 31, 2022 | -150.05% |
| Sep 30, 2022 | 188.99% |
| Jun 30, 2022 | -225.06% |
| Mar 31, 2022 | -134.22% |